Tempest Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Tempest Therapeutics

10/11/2021 22:56

* Tempest Therapeutics Inc  TPST.OQ  reported a quarterly
adjusted loss of $1.21​​ per share for the quarter ended in
September. The mean expectation of three analysts for the
quarter was for a loss of $1.05 per share.
* Reported revenue was zero​;  analysts expected zero. 
* Tempest Therapeutics Inc's reported EPS for the quarter was a
loss of $1.21​.
* The mean earnings estimate of analysts had fallen by
about 11.9% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Tempest Therapeutics Inc shares had fallen by 17.3% this
quarter and lost 62.7% so far this year.
* The company reported a quarterly loss of $8.11 million.
* Wall Street's median 12-month price target for Tempest
Therapeutics Inc is $37.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 10 at 10:56 p.m.
 ​All figures in US dollars unless otherwise stated